Evidence map›Paper›PMID 36101820›Full record

ArticleJIMD reports2022

A cross-sectional natural history study of aspartylglucosaminuria.

Kimberly Goodspeed, Daniel Horton, Andrea Lowden, Peter V Sguigna, Timothy Booth, Zhiyue J Wang, Veronica Bordes Edgar

Open access · goldAbstract read
In one paragraph

Article in JIMD reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kimberly GoodspeedDepartment of Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA.ORCID https://orcid.org/0000-0002-8823-2839
Daniel HortonChildren's Health Dallas Dallas Texas USA.
Andrea LowdenDepartment of Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA.ORCID https://orcid.org/0000-0002-3204-0790
Peter V SguignaDepartment of Neurology University of Texas Southwestern Medical Center Dallas Texas USA.ORCID https://orcid.org/0000-0003-1825-575X
Timothy BoothChildren's Health Dallas Dallas Texas USA.
Zhiyue J WangChildren's Health Dallas Dallas Texas USA.
Veronica Bordes EdgarDepartment of Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA.
Medical City Children's Hospital · USThe University of Texas Southwestern Medical Center · US

Funding

UT Southwestern Center for Translational MedicineKL2TR003981 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI ARGENBRIGHT, KEITH EDWARD, TRIVEDI, MADHUKAR H. · 2021 to 2025
$5.9M
6 · The paper itself

Abstract

Aspartylglucosaminuria (AGU) is a rare lysosomal storage disorder that causes stagnation of development in adolescence and neurodegeneration in early adulthood. Precision therapies, including gene transfer therapy, are in development with a goal of taking advantage of the slow clinical course. Understanding of disease natural history and identification of disease-relevant biomarkers are important steps in clinical trial readiness. We describe the clinical features of a diverse population of patients with AGU, including potential imaging and electrophysiological biomarkers. This is a single-center, cross-sectional study of the clinical, neuropsychological, electrophysiological, and imaging characteristics of AGU. A comprehensive assessment of eight participants (5 Non-Finnish) revealed a mean non-verbal IQ (NVIQ) of 70.25 ± 10.33 which decreased with age (rs = -0.85,

Indexed as

AGAaspartylglucosaminuriaelectrophysiologygene transfer therapylysosomal storage disorderneuroimaging

Identifiers

PMID36101820
PMCPMC9458605
OpenAlexW4285390921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.